Intuitive Surgical's shares dropped 6.3% following confirmation of an ongoing Class II worldwide recall impacting 454 components of its da Vinci surgical system. This recall, related to a faulty E-brake retainer pin, adds to a year-to-date decline of 31% ahead of the company’s Q2 earnings report scheduled for July 16. Analysts anticipate Q2 revenue of $2.81 billion and earnings per share of $2.48. The recall intensifies investor scrutiny on quality controls and regulatory oversight, even as Intuitive accelerates the rollout of its AI-enabled da Vinci 5 platform, which shows 11% higher utilization than its predecessor.
Adding to the pressure, HCA Healthcare, the largest for-profit hospital operator, revised its full-year earnings outlook after reporting a 2.3% decrease in inpatient surgeries and a 3.4% decline in outpatient procedures for Q2. This broader contraction in surgical volumes also led to declines in other medtech companies like Abbott Laboratories and Medtronic. Intuitive's stock closed at $379.50, reflecting heightened investor anxiety regarding surgical demand and potential impacts on its recurring revenue model, which contributed 86% of total revenue in Q1.
Despite the immediate challenges, including competition and pricing pressures in international markets like China and Japan, analysts maintain a cautiously optimistic long-term view. The average price target from five analysts was lowered by 8.8% to $543.20, but this still represents a 42% upside from the current price. Intuitive is working to diversify its product portfolio with the Ion robotic bronchoscopy system and the single-port da Vinci SP platform, which is gaining traction in urology and transoral head and neck surgeries. These efforts aim to offset reduced bariatric procedure volumes due to GLP-1 obesity drugs.
